Showing results (161-170 of 280) with videos related to

Sort By:
Pageof 28
British Journal of Haematology|July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSSAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Blood Advances|April 21, 2020
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United StatesAmer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Leukemia & Lymphoma|May 5, 2020
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experienceJan Philipp Bewersdorf, Rory M Shallis, Lohith Gowda, et al.
British Journal of Haematology|September 22, 2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromesAmer M Zeidan, Amy J Davidoff, Jessica B Long, et al.
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
American Journal of Hematology|June 2, 2005
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemiaSteven D Gore, B Douglas Smith, Ivana Gojo, et al.
Blood|December 21, 2006
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasIvana Gojo, Anchalee Jiemjit, Jane B Trepel, et al.
Leukemia & Lymphoma|February 7, 2020
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based surveyAlexander B Pine, Nora Chokr, Maximilian Stahl, et al.
Plos One|September 14, 2017
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based studyAmer M Zeidan, Jessica B Long, Rong Wang, et al.
Leukemia Research|March 5, 2016
A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemiaElizabeth A Griffiths, William E Brady, Wei Tan, et al.
Pageof 28